aibioIntellia Therapeutics gets up to $400 million term loan from OrbiMed
Tickers NTLA
Intellia Therapeutics will receive $75 million at closing under the facility. Up to $225 million more depends mainly on milestones for lonvo-z.
Key facts
- Company
- Intellia Therapeutics, Inc. (NASDAQ: NTLA)
- News type
- Debt Financing
- Primary source
- Intellia Therapeutics, Inc. 8-K (2026-09-04)
Intellia Therapeutics, Inc. entered into a $400 million senior secured term loan facility with OrbiMed, according to a press release filed as Exhibit 99.1 to a Form 8-K on September 4, 2026. The company describes the facility as non-dilutive, and OrbiMed is the lender. The initial term loan of $75 million was funded at closing.
Tranches, milestones and advisers
Five additional tranches totaling up to $225 million can be drawn at Intellia's option once specified milestones are met, mainly those tied to lonvo-z. The release does not define those milestones. A further $100 million is available only by mutual agreement during the five-year term.
Edward Dulac, Intellia's chief financial officer, said in the release that the financing lets the company more freely execute its plan to launch lonvo-z. OrbiMed's Matthew Rizzo called Intellia a well-recognized leader in in vivo gene editing. Both statements come from the two parties to the deal, not from independent sources.
The release gives no interest rate or maturity date, and Intellia says more details will be filed on a later Form 8-K. The release names no placement agent or underwriter. TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia, and Covington & Burling LLP acted as legal advisor to OrbiMed. The company's own risk list for the facility includes debt-service obligations, restrictive covenants, security interests and the potential for default.
The programs and the approval path
Lonvo-z is an in vivo CRISPR gene editing candidate for hereditary angioedema, given as a single infusion in an outpatient setting. The company says it could become the first one-time treatment for that disease. The release lists five regulatory designations for lonvo-z: Orphan Drug and RMAT designation from the U.S. Food and Drug Administration, an Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency, PRIME designation from the European Medicines Agency, and orphan designation from the European Commission. Designations are not approvals. Its annual report says Intellia is preparing for a commercial launch in the first half of 2027. The release refers to a planned U.S. approval and to review of a biologics license application for lonvo-z, so approval is still ahead. The annual report speaks of preparing for a potential positive Phase 3 readout, a filing and a launch.
The second lead candidate, nexiguran ziclumeran, targets transthyretin amyloidosis. The company says it is the first to advance in vivo genome editing candidates into Phase 3 development, and its annual report describes both lonvo-z and nexiguran ziclumeran as in Phase 3. Neither the release nor the annual report business section gives Phase 3 results for either candidate. The milestones that unlock the larger tranches are tied mainly to lonvo-z, so the larger tranches depend on lonvo-z progress, including a Phase 3 readout that the annual report still calls potential. The headline figure of up to $400 million also includes $100 million that needs mutual agreement; the release says $325 million is tied to milestones.
Losses and cash
Revenue was $67.7 million in 2025, up from $57.9 million in 2024. The net loss narrowed to $412.7 million in 2025 from $519.0 million in 2024, and research and development expense fell to $388.9 million from $466.3 million. Cash used in operations rose to $394.7 million in 2025 from $348.9 million in 2024.
At June 30, 2026, cash and cash equivalents were $106.1 million and short-term investments were $331.6 million. The $75 million funded at closing is small against the $394.7 million used in operations in 2025. The company's own list of uses says the money will launch lonvo-z in HAE, advance nexiguran ziclumeran through milestones in ATTR amyloidosis, and fund early pipeline work. Intellia said more details of the loan agreement will be filed on a later Form 8-K.